An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors.

Authors

Kaiwen Li

Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Kaiwen Li , Yehui Shi , Junyan Wu , Liyan Zhou , Suiwen Ye , Xiuping Lai , Robert Huang , Yan Teng , Jiangang Yu , Xiaoyan Chai , Hai Huang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.

First Author: Ramaswamy Govindan

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRAS^G12C inhibitor, in advanced solid tumors.

First Author: Yan Zhang

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors.

First Author: Kyriakos P. Papadopoulos

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

A phase I, open-label, multicenter dose escalation study to assess the safety, tolerability, and pharmacokinetics of AZD2811 nanoparticle in patients with advanced solid tumors.

First Author: Melissa Lynne Johnson